Key HIV Studies Influencing My Practice Following IDWeek and HIV Glasgow 2022—Audio Recap

In this episode, Chloe Orkin, MBChB, FRCP, MD, and Babafemi Taiwo, MBBS, discuss new HIV data presented at IDWeek and HIV Glasgow 2022, including

• Prevention strategies
  • Updated data from HPTN 083 evaluating LA CAB for PrEP in men who have sex with men and transgender women
  • Data on awareness and use of PrEP among cisgender women in the United States

• LA therapies
  • Data from an expanded multivariable analysis of factors associated with virologic failure of LA CAB + RPV
  • Data from the OPERA cohort on outcomes during the first year of real-world LA CAB + RPV use in the United States
  • Data from the CARLOS cohort on 6-month outcomes of real-world LA CAB + RPV use in Germany
  • Safety, efficacy, and adherence data from the CARISEL phase IIIb implementation study of LA CAB + RPV use in Europe
  • Week 52 efficacy, safety, and lenacapavir resistance data from the CAPELLA trial

• Investigational agents
  • Post hoc analysis of P011 evaluating dose-dependent islatravir effect on lymphocytes
  • Modeling and simulation study to identify optimal islatravir dosing for clinical development